E815
TEAS SECTION 8 & 15 RECEIVED
06/09/2026
Back to search
Official data from USPTO
AMGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
AMGEN
ST13
US500000086834490Class
5, 10, 35, 36, 41, 42, 44
Filing
86834490
Registration
6080333
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
71
Latest update
06/10/2026
Trademark type
Word
Nice classes
5, 10, 35, 36, 41, 42, 44
Filing date
11/30/2015
Registration date
06/16/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/16/2020
Last transaction
06/10/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/01/1990
First use in commerce
01/01/1990
Drawing code
4
Owner type
03
Owner location
Thousand Oaks, CA, US
Examiner
TOY, JOSHUA SPENCER JOLL
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Amgen Inc.
Representatives
Elsa D. Lemoine Amgen Inc.
Technical classification
Nice Classes
Class 5Class 10Class 35Class 36Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for the treatment of cardiovascularcancerboneneurological nephrological and inflammation disease and disorders; pharmaceutical preparations for the treatment of anemiaankylosing spondylitisarthritiscancercardiovascular conditionscollection by leukopheresiseffects of myelosuppressive chemotherapyeffects of myelosuppressive doses of radiationglandular disordershormone disordershypercalcemiahyperparathyroidismhyperphosphatemiakidney disorders and diseasemigraineneutropeniaosteoporosisparathyroid disorderspsoriasisreduction of red blood cell transfusionsrenal disordersthrombocytopenia; prescription pharmaceuticals for the treatment of anemiaankylosing spondylitisarthritiscancercardiovascular conditionscollection by leukopheresiseffects of myelosuppressive chemotherapyeffects of myelosuppressive doses of radiationglandular disordershormone disordershypercalcemiahyperparathyroidismhyperphosphatemiakidney disorders and diseasemigraineneutropeniaosteoporosisparathyroid disorderspsoriasisreduction of red blood cell transfusionsrenal disordersthrombocytopenia; and pre-filled syringes and vials containing pharmaceutical preparations for the treatment of the aforementioned diseases and disorders and complications associated therewith
Class 10
Drug delivery devices in the nature of drug delivery systems; drug delivery systems; injection device for pharmaceutical preparations; injectors for medical purposes in the nature of medical fluid injectors
Class 35
Online wholesale services by direct solicitation by salespersons directed to end-users featuring pharmaceuticals; referral services in the field of treatment for cancerchemotherapy and pharmaceutical products in the nature of medical referrals; business administration of prescription drug co-payment programs; business administration of patient reimbursement programs; referral services in the field of co-pay assistance programs in the nature of providing insurance agent referrals; providing an online commercial information directory in the field of patient support featuring information regarding healthcare providerssites at which subcutaneous injections could be administered and retail pharmacies or specialty pharmacies where patients could obtain pharmaceutical preparations
Class 36
Providing healthcare administrationproviding insurance verification and prior authorization services for others
Class 41
Educational servicesdevelopment and dissemination of printed educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting seminars in the field of the use of prescription pharmaceutical products for medical disorders; educational and entertainment servicesproviding a motivational and educational speaker featuring information regarding medical disorders; training services in the field of patient support services relating to treatment of medical disorders; providing on-line electronic newsletters delivered by email in the field of the treatment of medical disorders
Class 42
Pharmaceutical research and development services; biological research; chemical research; medical researchconducting clinical trials for others
Class 44
Patient support services relating to the treatment of medical disordersproviding online information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services via a global computer network; providing health and medical information about medical disorders; information servicesproviding medical information to cancer patients; providing patient support services relating to cancer and cancer treatment in the nature of an Internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; providing information about bone health in patients with cancer by offering customized medical information and practical advice for communicating about bone health with healthcare providers; information servicesproviding medical consultancy and advisory services via a global computer network in the field of cancer-related bone health; providing medical information and patient support servicesproviding pharmaceutical advice and consultation in the nature of providing online information regarding bone healththe prevention of osteoporosis and the treatment and management of osteoporosis and bone diseasepharmaceutical preparations for the treatment of osteoporosis; medical report services in the nature of providing medical reports regarding patients being treated for osteoporosis and bone disease; providing medical consultancy and advisory services via a global computer network in the field of cancer treatment and chemotherapy; providing medical information and patient support servicespharmaceutical advice and consultation in the nature of providing online information regarding immune thrombocytopenic purpura; providing health and medical information about immune thrombocytopenic purpura; information servicesproviding medical information to immune thrombocytopenic purpura patients; patient support services relating to treatment of medical disordersproviding information to patients and families of patients in the field of administering medicationpatient medical information where patients can inquire about medical issues and procedures from medical personnel
Publications
History of USPTO decisions and trademark events.
71 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/16/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/25/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/25/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/25/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/25/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/25/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/29/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/29/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/29/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/29/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/29/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/29/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
06/16/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/15/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/14/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/29/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/28/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/28/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/28/2019
GNRT
NON-FINAL ACTION E-MAILED
10/28/2019
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/28/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/12/2019
IUAF
USE AMENDMENT FILED
10/10/2019
EISU
TEAS STATEMENT OF USE RECEIVED
10/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/04/2019
EX5G
SOU EXTENSION 5 GRANTED
04/03/2019
EXT5
SOU EXTENSION 5 FILED
03/28/2019
EEXT
SOU TEAS EXTENSION RECEIVED
03/28/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/07/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/07/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/11/2018
EX4G
SOU EXTENSION 4 GRANTED
09/07/2018
EXT4
SOU EXTENSION 4 FILED
09/07/2018
EEXT
SOU TEAS EXTENSION RECEIVED
09/07/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/02/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/02/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/16/2018
EX3G
SOU EXTENSION 3 GRANTED
03/15/2018
EXT3
SOU EXTENSION 3 FILED
03/13/2018
EEXT
SOU TEAS EXTENSION RECEIVED
03/13/2018
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/13/2017
EX2G
SOU EXTENSION 2 GRANTED
09/12/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/12/2017
EXT2
SOU EXTENSION 2 FILED
08/31/2017
EEXT
SOU TEAS EXTENSION RECEIVED
08/31/2017
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/29/2017
EX1G
SOU EXTENSION 1 GRANTED
03/27/2017
EXT1
SOU EXTENSION 1 FILED
03/27/2017
EEXT
SOU TEAS EXTENSION RECEIVED
03/27/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/11/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2016
PUBO
PUBLISHED FOR OPPOSITION
08/16/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/14/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
07/13/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/13/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
07/13/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/13/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/11/2016
GNFR
FINAL REFUSAL E-MAILED
05/11/2016
CNFR
FINAL REFUSAL WRITTEN
05/11/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/20/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/20/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/08/2016
GNRT
NON-FINAL ACTION E-MAILED
01/08/2016
CNRT
NON-FINAL ACTION WRITTEN
01/08/2016
DOCK
ASSIGNED TO EXAMINER
01/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/04/2015
NWAP
NEW APPLICATION ENTERED
12/03/2015
Continuous trademark protection
Get notified about every new filing that threatens AMGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.